Imunon (IMNN) Competitors $0.79 -0.01 (-1.13%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$0.80 +0.01 (+0.63%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. AVTX, IPA, RENB, KLRS, BLUE, ADVM, VRCA, DTIL, AADI, and ATRAShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Avalo Therapeutics (AVTX), ImmunoPrecise Antibodies (IPA), Renovaro (RENB), Kalaris Therapeutics (KLRS), bluebird bio (BLUE), Adverum Biotechnologies (ADVM), Verrica Pharmaceuticals (VRCA), Precision BioSciences (DTIL), Aadi Bioscience (AADI), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Its Competitors Avalo Therapeutics ImmunoPrecise Antibodies Renovaro Kalaris Therapeutics bluebird bio Adverum Biotechnologies Verrica Pharmaceuticals Precision BioSciences Aadi Bioscience Atara Biotherapeutics Imunon (NASDAQ:IMNN) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation. Which has more volatility & risk, IMNN or AVTX? Imunon has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Which has preferable valuation & earnings, IMNN or AVTX? Imunon has higher revenue and earnings than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K27.75-$18.62M-$1.36-0.58Avalo Therapeutics$441K123.01-$35.13MN/AN/A Do insiders and institutionals have more ownership in IMNN or AVTX? 4.5% of Imunon shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 6.0% of Imunon shares are owned by company insiders. Comparatively, 3.0% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to IMNN or AVTX? In the previous week, Imunon and Imunon both had 2 articles in the media. Avalo Therapeutics' average media sentiment score of 0.51 beat Imunon's score of -0.04 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avalo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IMNN or AVTX more profitable? Avalo Therapeutics' return on equity of 111.00% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -427.98% -175.03% Avalo Therapeutics N/A 111.00%58.88% Do analysts rate IMNN or AVTX? Imunon currently has a consensus price target of $15.50, indicating a potential upside of 1,859.54%. Avalo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 498.80%. Given Imunon's higher possible upside, equities analysts clearly believe Imunon is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAvalo Therapeutics beats Imunon on 7 of the 13 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.03M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.5821.5627.4020.24Price / Sales27.75281.35419.60118.25Price / CashN/A41.9536.6357.47Price / Book2.737.518.085.67Net Income-$18.62M-$55.05M$3.16B$248.47M7 Day Performance6.89%4.71%2.84%3.32%1 Month Performance-53.47%4.89%3.69%5.20%1 Year Performance-34.90%5.82%35.30%21.35% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.482 of 5 stars$0.79-1.1%$15.50+1,859.5%-34.1%$14.03M$500K-0.5830News CoverageAVTXAvalo Therapeutics3.0694 of 5 stars$4.99+4.4%$30.00+501.2%-57.0%$51.76M$440K0.0040News CoverageIPAImmunoPrecise Antibodies1.7657 of 5 stars$1.06-4.5%$4.00+277.4%+33.5%$50.80M$18.16M-0.9180News CoverageRENBRenovaro1.1866 of 5 stars$0.29-1.3%N/A-82.4%$50.38MN/A-0.3820KLRSKalaris TherapeuticsN/A$2.67+1.9%N/AN/A$49MN/A0.00110Positive NewsGap UpBLUEbluebird bio2.1245 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News CoverageADVMAdverum Biotechnologies4.2542 of 5 stars$2.15-7.3%$23.80+1,007.0%-66.5%$48.47M$1M-0.34190VRCAVerrica Pharmaceuticals3.934 of 5 stars$0.53+1.4%$8.00+1,409.1%-90.8%$48.34M$7.57M-0.4440DTILPrecision BioSciences4.5812 of 5 stars$4.20-2.3%$47.00+1,019.0%-52.9%$47.68M$68.70M-2.09200AADIAadi Bioscience0.6706 of 5 stars$1.93+1.6%$1.67-13.6%+34.3%$47.67M$25.07M-0.8540ATRAAtara Biotherapeutics4.1269 of 5 stars$7.72-3.0%$17.75+129.9%+3.9%$47.45M$128.94M-2.08330 Related Companies and Tools Related Companies AVTX Competitors IPA Competitors RENB Competitors KLRS Competitors BLUE Competitors ADVM Competitors VRCA Competitors DTIL Competitors AADI Competitors ATRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
